Findings from the current study demonstrate that over half of chronic HF patients in the DIG trial had severe and more advanced disease as evidenced by the presence of NYHA III–IV symptoms, LVEF <25%, ...
The heart drug digoxin could potentially be combined with existing cancer therapies to prevent the spread of tumors, an early trial suggests. But questions remain. When you purchase through links on ...
Wearable device data could predict New York Heart Association functional class similarly to clinical measures and six-minute walk test. HealthDay News — For patients with atrial fibrillation, digoxin ...
Senior researcher Dr Ali Ahmed (University of Alabama, Birmingham) told heartwire that the differing conclusions are the result of two different methodologies used to analyze the data. He said their ...
MADRID, Spain—Adding digitoxin, a cardiac glycoside, to contemporary guideline-directed medical therapy (GDMT) improves clinical outcomes in patients who have heart failure with reduced ejection ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback